Discover the elements of efficacy and safety with TREANDA

TREANDA is a uniquely designed single-agent therapy that is indicated for indolent B-cell NHL that has progressed. In the phase 3 multicenter trial, TREANDA produced a robust 74% overall response rate (ORR) (95% CI: 64.3, 82.3) in patients previously treated with and resistant to rituximab-containing regimens and delivered durable response rates that lasted a median of 9.2 months (95% CI: 7.1, 10.8).

TREANDA was also generally well tolerated in 2 clinical studies. Sixty-two percent of patients in the pivotal trial did not receive granulocyte growth factor support. Prophylactic use of growth factors was allowed in conjunction with the study drug; use was discouraged during the first treatment cycle. Investigators were advised to follow the American Society of Clinical Oncology (ASCO) guidelines.^1,2

The most common non-hematologic adverse reactions (frequency ≥30%) were nausea (75%), fatigue (57%), vomiting (40%), diarrhea (37%), and pyrexia (34%) (N=176). The most common hematologic abnormalities (frequency ≥15%) were lymphopenia (99%), leukopenia (94%), anemia (88%), neutropenia (86%), and thrombocytopenia (86%).

Additionally, TREANDA is a uniquely designed agent that may cause dual cell death via multiple pathways.^3-6 The exact mechanism of TREANDA is unknown. Adverse reactions may require interventions such as decreasing the dose of TREANDA or withholding or delaying treatment.

Please explore the site to learn more about the clinical efficacy of prescribing TREANDA for your patients with indolent B-cell NHL that has progressed. You’ll also find helpful educational resources and reimbursement assistance and support that may benefit you and your patients.

Indications

TREANDA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established.

TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.

Important Safety Information

• Serious adverse reactions, including myelosuppression, infections, infusion reactions and anaphylaxis, tumor lysis syndrome, skin reactions including SJS/TEN, other malignancies, and extravasation, have been associated with TREANDA. Some reactions, such as myelosuppression, infections, and SJS/TEN (when TREANDA was administered concomitantly with allopurinol and other medications known to cause SJS/TEN), have been fatal. Patients should be monitored closely for these reactions and treated promptly if any occur
  
  
• Adverse reactions may require interventions such as decreasing the dose of TREANDA, or withholding or delaying treatment
  
  
• TREANDA is contraindicated in patients with a known hypersensitivity to bendamustine or mannitol. Women should be advised to avoid becoming pregnant while using TREANDA
  
  
• The most common non-hematologic adverse reactions associated with TREANDA (frequency ≥30%) were nausea, fatigue, vomiting, diarrhea, and pyrexia. The most common hematologic abnormalities associated with TREANDA (frequency ≥15%) were lymphopenia, leukopenia, anemia, neutropenia, and thrombocytopenia

TO REPORT SIDE EFFECTS: Contact us at 1-800-896-5855 or usmedinfo@cephalon.com